Long-Term Clinical Study Conducted with Leading U.S. Retinal Specialists on IVT Patients
Safety and Pain Relief of Repeated IVT Procedures Confirmed in SCI-Grade International Journal

RESCENE Medical’s Rapid Cooling Anesthesia Technology Published in ‘PLOS ONE’... “Demonstrated Safety and Pain Relief Effects” View original image

LISENSE Medical, a company specializing in precision-cooling medical devices and co-led by Kim Geonho and Choi Uikyung, announced on October 7 that the results of a long-term clinical study of its rapid cooling anesthesia technology in patients with retinal diseases requiring repeated intravitreal (IVT) injections had been published in the SCI-indexed international journal PLOS ONE.


Notably, leading U.S. retinal specialists, including Dr. Arshad M. Khanani, Dr. Charles C. Wykoff, and Dr. Ajay E. Kuriyan, participated as co-investigators. These researchers conduct research and provide clinical care at major U.S. ophthalmology institutions and university hospitals. The study was published in PLOS ONE after undergoing rigorous peer review.


IVT injections, used to treat retinal diseases such as macular degeneration and diabetic retinopathy, are a common treatment that patients may need to receive repeatedly every month over a period of months or years. During this process, patients may experience recurring pain, wait times for anesthesia to take effect, and psychological stress, in addition to the procedure itself. The researchers assessed the level of pain associated with rapid cooling anesthesia and its safety with repeated use under different cooling temperatures and application times. The results showed that the cooling anesthesia device relieved pain during IVT procedures. In particular, among patients who received cooling anesthesia at -15 degrees C for 10 seconds, 81.5% preferred it over the anesthesia method they had previously experienced after their first procedure.


LISENSE Medical's ophthalmic anesthesia device OcuCool, which uses the rapid cooling anesthesia technology described in the paper, provides immediate anesthesia within seconds, without the need to wait for medication to take effect. Anesthesia and the IVT procedure can be performed virtually at the same time, reducing the overall time patients spend at the clinic. This can help hospitals maximize operational efficiency by reducing the burden on nursing staff and the space required to manage waiting patients, while enabling doctors to treat more patients in the same amount of time without schedule delays. Patients, in turn, can significantly reduce the long waits they face during each visit. The company expects the device's features to help improve the efficiency of IVT procedures and reduce the burden they place on patients.


This environment, which allows procedures to be performed immediately, is expected to create a virtuous cycle that not only improves the operational efficiency and profitability of medical institutions but also provides more patients with timely access to treatment.


As demand for IVT procedures to treat retinal diseases continues to rise due to population aging and the growing number of people with diabetes, reducing the burden on patients during repeated procedures and establishing an efficient procedural environment have emerged as important challenges. In 2024, LISENSE Medical obtained U.S. FDA De Novo approval for OcuCool and is currently discussing global partnerships and clinical collaborations to commercialize the device.



A representative of LISENSE Medical said, "The publication in PLOS ONE is significant because it means that long-term clinical results obtained by U.S. retinal specialists treating actual patients have been published in an international journal. We will continue to build objective clinical evidence through ongoing research and collaboration with world-renowned medical professionals, further strengthening our technological competitiveness in the global medical device market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing